drug · small molecule
omacetaxine mepesuccinate
Marketedupdated 3mo agoby $TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and chronic myelogenous leukemia and 7 investigational indications.
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 26, 2026
72 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Oct 26, 2026method-of-use (U-1300)US 698710372d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that